Blonder Tongue Laboratories Inc
BDR was delisted on the 24th of June, 2022.
0 hedge funds and large institutions have $0 invested in Blonder Tongue Laboratories Inc in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 11 closing their positions.
100% less funds holding
Funds holding: 11 → 0 (-11)
100% less capital invested
Capital invested by funds: $391K → $0 (-$391K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 11
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tufton Capital Management
Hunt Valley,
Maryland
|
-$120K |
| 2 |
Renaissance Technologies
New York
|
-$64K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$58K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$52K |
| 5 |
State Street
Boston,
Massachusetts
|
-$42K |
BDR Hedge Fund Activity: Q2 2022 in Review
0 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Blonder Tongue Laboratories Inc (BDR) for Q2 2022, worth a combined $0 — down 100% from $391K a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of BDR and 0 opened new positions — a net loss of 11 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Tufton Capital Management, exiting entirely with an estimated $120K sold.
- 0 institutional investors held Blonder Tongue Laboratories Inc (BDR) as of Q2 2022, down from 11 in Q1 2022.
- Funds reported $0 of Blonder Tongue Laboratories Inc stock for Q2 2022, down 100% quarter-over-quarter.
- 0 funds opened new Blonder Tongue Laboratories Inc positions in Q2 2022 and 11 closed out, a net change of -11 holders.
- The largest Blonder Tongue Laboratories Inc seller in Q2 2022 was Tufton Capital Management, an estimated $120K sold.
Based on aggregated 13F filings for Q2 2022.